# Sodium Channel Blockers {#id}

Sodium channel blockers include:
* Class Ia:
    * **Procainamide**
    * Quinidine
    * Disopyramide
* Class Ib:
    * **Lignocaine**
    * Mexiletine (lignocaine analogue)
* Class Ic:
    * **Flecainide**

In general:
* IV preparations are given for VT
* Good PO bioavailability and low protein binding
* Metabolites are renally cleared

|Property|Procainamide|Lignocaine|Flecainide|
|--|--|
|**Class**|Class Ia amide|Class Ib amide local anaesthetic|Class Ic amide local anaesthetic|
|**Uses**|SVT/VT|VT|SVT/VT|
|**Presentation**||Clear solution at 10-20mg.ml<sup>-1</sup> (1-2%)||
|**Route of Administration**|PO/IV|IV|PO/IV|
|**Dosing**|100mg IV load, followed by infusion at 2-6mg.ml<sup>-1</sup>|Load at 1mg.kg<sup>-1</sup> followed by infusion at 1-3mg.min<sup>-1</sup>|2mg.kg<sup>-1</sup> (up to 150mg) load over 10-30 minutes, followed by infusion at 1.5mg.kg<sup>-1</sup>.hr<sup>-1</sup>, aiming for levels of <0.9mg/ml
|**Absorption**|75% bioavailability|IV only for arrhythmia|90% orally bioavailable|
|**Distribution**||33% unionised, 70% protein bound|50% protein bound|
|**Metabolism**|Hepatic to active metabolites via acetylation - slow acetylators at increased risk of side effects|Hepatic amidases to inactive metabolites|Hepatic to active metabolites|
|**Mechanism of Action**| Reduces the rate of rise of phase 0, raises the threshold potential, and prolongs the refractory period without prolonging the action potential|Reduces the rate of rise of phase 0 of the action potential. Repolarisation phase is shortened.|Reduces the rate of rise of phase 0 0of the action potential. Repolarisation is unchanged.|
|**CVS**|↓ HR, ↓SVR, ↓BP, ↓CO, heart block, may ↑HR when used for SVT, ↑QT with risk of TDP|AV block, myocardial depression causing unresponsive ↓BP|Precipitate pre-existing conduction disorders, ↓ inotropy, ↑ pacing and defibrillation threshold|
|**CNS**||Circumoral tingling, dizziness, parasthesia, confusion, seizures, coma|Dizziness, parasthesia, headache|
|**Immune**|Lupoid syndrome in 20-30%, reduces antimicrobial effect of sulfonamides|||
|**Interactions**|||Pharmacokinetic interactions with digoxin, propranolol, amiodarone|


---

##References
1. Peck TE, Hill SA. Pharmacology for Anaesthesia and Intensive Care. 4th Ed. Cambridge University Press. 2014.  
2. Smith S, Scarth E, Sasada M. Drugs in Anaesthesia and Intensive Care. 4th Ed. Oxford University Press. 2011.